1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?
Abstract Background ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E. Methods In this multicenter study, patients with ALK+ NS...
Gespeichert in:
| Veröffentlicht in: | Annals of oncology 2019-10, Vol.30 (Supplement_5) |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | Supplement_5 |
| container_start_page | |
| container_title | Annals of oncology |
| container_volume | 30 |
| creator | Kilickap, S Buğdaycı Başal, F Demirkazik, A Gursoy, P Demirci, U Erman, M Yumuk, F Cay Senler, F Cakar, B Cicin, I Ozturk, A Coskun, H S Çubukçu, E Işıkdoğan, A Olmez, O F Tatlı, A M Karaagac, M Şakalar, T Eralp, Y Korkmaz, T |
| description | Abstract
Background
ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E.
Methods
In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC.
Results
Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.
Conclusions
Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest. |
| doi_str_mv | 10.1093/annonc/mdz260.069 |
| format | Article |
| fullrecord | <record><control><sourceid>oup</sourceid><recordid>TN_cdi_oup_primary_10_1093_annonc_mdz260_069</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/annonc/mdz260.069</oup_id><sourcerecordid>10.1093/annonc/mdz260.069</sourcerecordid><originalsourceid>FETCH-oup_primary_10_1093_annonc_mdz260_0693</originalsourceid><addsrcrecordid>eNqVj8tKxDAYRoMoWC8P4O5fKphp0tvYlUgZcXCQAd2H0ElnfmmTkKSVceOrGx1fwNX3Lc5ZHEKuOJtxVuep1NroNh02n1nFZqyqj0jCy6qmd6zgxyRhdZbTeZkXp-TM-3fGIpLVCfniZTFfLz2EnXIKpN6DdWarjQ_Ygsetxg5bqVsFqMH2anSyj3cy_aQGpUNUNqlxoLpu9Gg0XK97RZfp4uZXkAEj5OEDww4eVs_UGo8BJwUvr82qub8gJ53svbr823Ny-7h4a56oGa2wDgfp9oIz8RMpDpHiECliQf5P_Bu7jFyx</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Kilickap, S ; Buğdaycı Başal, F ; Demirkazik, A ; Gursoy, P ; Demirci, U ; Erman, M ; Yumuk, F ; Cay Senler, F ; Cakar, B ; Cicin, I ; Ozturk, A ; Coskun, H S ; Çubukçu, E ; Işıkdoğan, A ; Olmez, O F ; Tatlı, A M ; Karaagac, M ; Şakalar, T ; Eralp, Y ; Korkmaz, T</creator><creatorcontrib>Kilickap, S ; Buğdaycı Başal, F ; Demirkazik, A ; Gursoy, P ; Demirci, U ; Erman, M ; Yumuk, F ; Cay Senler, F ; Cakar, B ; Cicin, I ; Ozturk, A ; Coskun, H S ; Çubukçu, E ; Işıkdoğan, A ; Olmez, O F ; Tatlı, A M ; Karaagac, M ; Şakalar, T ; Eralp, Y ; Korkmaz, T</creatorcontrib><description>Abstract
Background
ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E.
Methods
In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC.
Results
Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.
Conclusions
Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.</description><identifier>ISSN: 0923-7534</identifier><identifier>EISSN: 1569-8041</identifier><identifier>DOI: 10.1093/annonc/mdz260.069</identifier><language>eng</language><publisher>Oxford University Press</publisher><ispartof>Annals of oncology, 2019-10, Vol.30 (Supplement_5)</ispartof><rights>European Society for Medical Oncology 2019. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oup.com. 2019</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids></links><search><creatorcontrib>Kilickap, S</creatorcontrib><creatorcontrib>Buğdaycı Başal, F</creatorcontrib><creatorcontrib>Demirkazik, A</creatorcontrib><creatorcontrib>Gursoy, P</creatorcontrib><creatorcontrib>Demirci, U</creatorcontrib><creatorcontrib>Erman, M</creatorcontrib><creatorcontrib>Yumuk, F</creatorcontrib><creatorcontrib>Cay Senler, F</creatorcontrib><creatorcontrib>Cakar, B</creatorcontrib><creatorcontrib>Cicin, I</creatorcontrib><creatorcontrib>Ozturk, A</creatorcontrib><creatorcontrib>Coskun, H S</creatorcontrib><creatorcontrib>Çubukçu, E</creatorcontrib><creatorcontrib>Işıkdoğan, A</creatorcontrib><creatorcontrib>Olmez, O F</creatorcontrib><creatorcontrib>Tatlı, A M</creatorcontrib><creatorcontrib>Karaagac, M</creatorcontrib><creatorcontrib>Şakalar, T</creatorcontrib><creatorcontrib>Eralp, Y</creatorcontrib><creatorcontrib>Korkmaz, T</creatorcontrib><title>1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?</title><title>Annals of oncology</title><description>Abstract
Background
ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E.
Methods
In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC.
Results
Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.
Conclusions
Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.</description><issn>0923-7534</issn><issn>1569-8041</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid/><recordid>eNqVj8tKxDAYRoMoWC8P4O5fKphp0tvYlUgZcXCQAd2H0ElnfmmTkKSVceOrGx1fwNX3Lc5ZHEKuOJtxVuep1NroNh02n1nFZqyqj0jCy6qmd6zgxyRhdZbTeZkXp-TM-3fGIpLVCfniZTFfLz2EnXIKpN6DdWarjQ_Ygsetxg5bqVsFqMH2anSyj3cy_aQGpUNUNqlxoLpu9Gg0XK97RZfp4uZXkAEj5OEDww4eVs_UGo8BJwUvr82qub8gJ53svbr823Ny-7h4a56oGa2wDgfp9oIz8RMpDpHiECliQf5P_Bu7jFyx</recordid><startdate>20191001</startdate><enddate>20191001</enddate><creator>Kilickap, S</creator><creator>Buğdaycı Başal, F</creator><creator>Demirkazik, A</creator><creator>Gursoy, P</creator><creator>Demirci, U</creator><creator>Erman, M</creator><creator>Yumuk, F</creator><creator>Cay Senler, F</creator><creator>Cakar, B</creator><creator>Cicin, I</creator><creator>Ozturk, A</creator><creator>Coskun, H S</creator><creator>Çubukçu, E</creator><creator>Işıkdoğan, A</creator><creator>Olmez, O F</creator><creator>Tatlı, A M</creator><creator>Karaagac, M</creator><creator>Şakalar, T</creator><creator>Eralp, Y</creator><creator>Korkmaz, T</creator><general>Oxford University Press</general><scope/></search><sort><creationdate>20191001</creationdate><title>1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?</title><author>Kilickap, S ; Buğdaycı Başal, F ; Demirkazik, A ; Gursoy, P ; Demirci, U ; Erman, M ; Yumuk, F ; Cay Senler, F ; Cakar, B ; Cicin, I ; Ozturk, A ; Coskun, H S ; Çubukçu, E ; Işıkdoğan, A ; Olmez, O F ; Tatlı, A M ; Karaagac, M ; Şakalar, T ; Eralp, Y ; Korkmaz, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-oup_primary_10_1093_annonc_mdz260_0693</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kilickap, S</creatorcontrib><creatorcontrib>Buğdaycı Başal, F</creatorcontrib><creatorcontrib>Demirkazik, A</creatorcontrib><creatorcontrib>Gursoy, P</creatorcontrib><creatorcontrib>Demirci, U</creatorcontrib><creatorcontrib>Erman, M</creatorcontrib><creatorcontrib>Yumuk, F</creatorcontrib><creatorcontrib>Cay Senler, F</creatorcontrib><creatorcontrib>Cakar, B</creatorcontrib><creatorcontrib>Cicin, I</creatorcontrib><creatorcontrib>Ozturk, A</creatorcontrib><creatorcontrib>Coskun, H S</creatorcontrib><creatorcontrib>Çubukçu, E</creatorcontrib><creatorcontrib>Işıkdoğan, A</creatorcontrib><creatorcontrib>Olmez, O F</creatorcontrib><creatorcontrib>Tatlı, A M</creatorcontrib><creatorcontrib>Karaagac, M</creatorcontrib><creatorcontrib>Şakalar, T</creatorcontrib><creatorcontrib>Eralp, Y</creatorcontrib><creatorcontrib>Korkmaz, T</creatorcontrib><jtitle>Annals of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kilickap, S</au><au>Buğdaycı Başal, F</au><au>Demirkazik, A</au><au>Gursoy, P</au><au>Demirci, U</au><au>Erman, M</au><au>Yumuk, F</au><au>Cay Senler, F</au><au>Cakar, B</au><au>Cicin, I</au><au>Ozturk, A</au><au>Coskun, H S</au><au>Çubukçu, E</au><au>Işıkdoğan, A</au><au>Olmez, O F</au><au>Tatlı, A M</au><au>Karaagac, M</au><au>Şakalar, T</au><au>Eralp, Y</au><au>Korkmaz, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC?</atitle><jtitle>Annals of oncology</jtitle><date>2019-10-01</date><risdate>2019</risdate><volume>30</volume><issue>Supplement_5</issue><issn>0923-7534</issn><eissn>1569-8041</eissn><abstract>Abstract
Background
ALK mutation occurs in approximately 3-5% of patients with NSCLC. At the baseline, Ple-I/E are more frequent in ALK+ patients with NSCLC. In the study, we aimed to evaluate characteristics of ALK+ patients who have Ple-I/E.
Methods
In this multicenter study, patients with ALK+ NSCLC who have Ple-I/E were retrospectively analyzed. Clinical and demographic characteristics of the disease, response rates, median PFS and OS were evaluated in 362 ALK+ patients with NSCLC.
Results
Of the patients, 198 (54.7%) were male. The median age at the time of diagnosis was 54 (21-85) years. The median age was higher in male (57 vs 52 years; p = 0.011). The most common histology was adenocarcinoma (100%). At the baseline, 57 (15.7%) patients had Ple-I/E. The median age of patients with Ple-I/E was similar to patients without Ple-I/E (53 vs 55 years; p = 0.541). The rate of smokers was 43.4% (n = 157) in the patients. There was no association between Ple-I/E and gender, lung metastasis and distant LAP metastasis. Pleural involvement was higher in non-smokers than smokers (19.4% vs 13.4%; p = 0.077), but not statistically significant. The frequencies of liver, brain and bone metastasis were a significant higher in ALK+ patients with Ple-I/E compared to those with non-metastatasis (respectively 18.2% vs 4.8%, p = 0.008; 19.1% vs 4.8%, p = 0.002; 20.6% vs 8.9%, p = 0.003). The median PFS was longer in ALK+ patients who have Ple-I/E 18.7 vs 10.6 months, p = 0.017). The 1-, 2- and 3-year PFS were 59%, 36%, and 24% in patients with Ple-I/E and 47%, 24%, and 8% in patients with non-involvement. Similarly, the median OS was longer in ALK+ patients who have pleural involvement/infusion 44.6 vs 22.6 months, p = 0.051). The 1-, 2- and 3-year OS were 78%, 67%, and 57% in patients with Ple-I/E and 66%, 48%, and 34% in patients with non-involvement.
Conclusions
Brain, liver and bone metastases are lower in ALK+patients with Ple-I/E. Presentation with Ple-I/E in patients with ALK+ NSCLC is associated with longer overall and progression-free survival.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.</abstract><pub>Oxford University Press</pub><doi>10.1093/annonc/mdz260.069</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0923-7534 |
| ispartof | Annals of oncology, 2019-10, Vol.30 (Supplement_5) |
| issn | 0923-7534 1569-8041 |
| language | eng |
| recordid | cdi_oup_primary_10_1093_annonc_mdz260_069 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| title | 1547PIs there any prognostic significance in pleural involvement and/or effusion (Ple-I/E) in patients with ALK-positive NSCLC? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-25T05%3A11%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-oup&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=1547PIs%20there%20any%20prognostic%20significance%20in%20pleural%20involvement%20and/or%20effusion%20(Ple-I/E)%20in%20patients%20with%20ALK-positive%20NSCLC?&rft.jtitle=Annals%20of%20oncology&rft.au=Kilickap,%20S&rft.date=2019-10-01&rft.volume=30&rft.issue=Supplement_5&rft.issn=0923-7534&rft.eissn=1569-8041&rft_id=info:doi/10.1093/annonc/mdz260.069&rft_dat=%3Coup%3E10.1093/annonc/mdz260.069%3C/oup%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rft_oup_id=10.1093/annonc/mdz260.069&rfr_iscdi=true |